Arbutus to participate at h.c. wainwright bioconnect virtual conference

Warminster, pa., jan. 04, 2022 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis b virus infection and to treat coronaviruses (including covid-19), today announced that the company will participate in a virtual fireside chat at the h.c. wainwright bioconnect virtual conference taking place january 10 - 13, 2022.
ABUS Ratings Summary
ABUS Quant Ranking